
    
      This is a first-in-human, multi-center, open-label clinical study with separate Dose
      Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of
      KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies
      (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic
      options considered useful by the investigator have been exhausted.
    
  